Adam uses over 25 years of health, medical science and deep-tech experience to advance digital health solutions globally. As CEO of Previsior, he supports Australian innovation and advises businesses on sustainable and pragmatic commercial practices.

Holding a B.Pharm and an MBA, Adam is also an Adviser to the Federal Government’s Industry Growth Program. While he has been an Exec-in-Residence at ANDHealth, Adam started his journey with ANDHealth as a foundation partner, and has continued to contribute since. Despite his contributions, Adam admits to being picky about his coffee, and must apologise to many for this.

Aizaz Syed is Senior Portfolio and Investment Manager at Tenmile, the dedicated health technology investment business owned by Tattarang where he leads, originates and manages investments as well as coordinating the overall portfolio strategy.

He has spent the last 10 years investing in early-stage technologies particularly across deep tech, healthcare, software and manufacturing as well as providing strategy, financial and commercial advice in Australia. Prior to Tenmile, he was an Investment Director at early-stage investment firm Nightingale Partners and Corporate and Investment Banking at Bank of America Merrill Lynch. Aizaz graduated from the Australian National University with a Bachelor of Commerce and a Bachelor of Laws (Hons.).

He is currently serving as a non-executive director of Proton Intelligence (a medtech startup developing the world’s first continuous potassium monitor for chronic kidney disease and heart failure), Inventia Life Sciences (advanced high-throughput 3D cell models for drug discovery), Amaroq Therapeutics (first-in-class therapies targeting disease-driving long non-coding RNAs for oncology) and Oncko (computational systems to discover and optimize novel multi-drug cancer combinations). He also previously served on the board of Aravax – a phase 2 novel immunotherapy for treatment of peanut allergies.

Anne has over 30 years' experience in the health, medical research and policy sectors, including frontline experience developing and administering health and medical research policies and programs for NSW’s health system.

In 2025, she was awarded the Public Service Medal in the King's Birthday Honours List for outstanding public service to NSW in medical research and innovation. Anne joins ANDHealth following a distinguished career in public sector leadership, innovation and commercialisation at NSW Health. Widely recognised as one of Australia's leading architects of health and medical research commercialisation, Anne has designed and governed major public funding programs, most notably the NSW Medical Devices Fund, which has returned over A$2 billion in investment to NSW and delivered nearly 1.7 million devices into the global health system, and has since been adopted as the blueprint for the NSW Physical Sciences, BioSciences and Emerging Technology Commercialisation Fund. Her leadership has made a lasting contribution to Australia's innovation ecosystem.

A longtime advocate of diversity, Anne has worked throughout her career to advance opportunities for women and underrepresented groups in health and technology, and she is a mentor in the Industry Mentoring Networking in STEM (IMNIS) initiative led by the Australian Academy of Technological Sciences and Engineering, of which she is an elected Fellow. Anne is also on LifeSciences Australia Board of Directors and is a member of Bioshores Ventures Advisory Board.

Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy. In 2017 she founded ANDHealth, an organisation that supports digital health companies in Australia by providing education, resources, non-dilutive funding and mentorship to help them navigate the complexities of the healthcare industry.

‍
ANDHealth is now one of Australia’s leading health technology commercialisation organisations with companies participating in its flagship ANDHealth+ program raising $19.70 in new capital and generating $6.70 in new revenues for every dollar invested. ANDHealth manages over $30M in public and private commitments to digital health commercialisation, and provides specialist support to a further $100M of funding managed by Brandon Capital.

‍
Bronwyn has been a Member of the Council of the National Health & Medical Research Council since 2021. She is also currently a Non-Executive Director of Lumos Diagnostics Ltd (ASX.LDX) alongside a number of other advisory roles.

Prior to joining Brandon Capital, Bob was Deputy Chief Medical Officer at Nucleus Network, Australia’s largest clinical trials unit. He was involved in overseeing and executing over 100 early phase clinical trials, including as Principal Investigator. He was also involved in overseeing Nucleus Network’s clinical operations, business development and expanding its trial capabilities.

During his time at Nucleus Network, he was appointed as the founding executive for Cardiora, a Brandon Capital investee company developing therapies for heart failure. He successfully led Cardiora through multiple phase 2 clinical trials. The program was subsequently licensed to a specialty pharmaceutical company.

Bob obtained his MD from The University of Melbourne and subsequently undertook his surgical residency in some of Australia’s leading academic hospitals, including the Royal Melbourne Hospital and Royal North Shore Hospital. He is a Graduate of the Australian Institute of Company Directors and currently lectures in the University of Melbourne’s MBA and Biodesign programs. Since joining Brandon, he has led investments both in Australia and in the US across therapeutic areas and also runs Brandon Capital’s training programs.

Dr Craig Rayner AM is Co-Founder and CEO of Oktopi, an AI-supported, human-guided platform transforming how medicines are developed. Oktopi integrates expert knowledge, automation, and portfolio decision support for biotech, pharma, and global health organisations.  

Craig's thesis is simple. The missing layer in drug development is not better prediction. It is better governance. Oktopi is built to close that gap. Craig has spent twenty-five years at the intersection of translational science, clinical pharmacology, global health, and new models for developing medicines.  

At Moderna he built the company's R&D footprint across Asia-Pacific as inaugural Director of the Regional Research Centre for Respiratory Medicines and Tropical Diseases, then led translational medicine programs. At Certara he founded and led Integrated Drug Development, a biosimulation consultancy supporting more than 90 percent of NDAs each year, co-led Certara Global Health, and as President helped take the company through its NASDAQ listed IPO - a unicorn listing at ~US$3.5 billion that peaked above US$7 billion. Earlier he co-founded and led d3 Medicine, and held senior roles at Roche and CSL.  

Craig is a Distinguished Alumnus and Adjunct Professor at Monash University. He has authored more than 120 publications across journals including NEJM, Lancet, Science, and CPT, and has engaged every major global health authority, including multiple FDA advisory committees. He is an elected Fellow of the Royal College of Physicians of Edinburgh, the Australian Academy of Health and Medical Sciences, and the Australian Academy of Technology and Engineering. In 2025 he was made a Member of the Order of Australia and added to the Prime Minister's Australian COVID Honour Roll.

Dr David Hau joined the Devices Clinical Section of the TGA in 2015. As a senior medical adviser, he currently leads the clinical assessment workstream for conformity assessment applications, and has worked as a clinical assessor in both premarket and postmarket contexts.

Dr Hau is a TGA representative currently at the IMDRF AIMD and SaMD Working Groups and at the Standards Australia HE-12 Committee on Surgical Implants. Trained in medicine and with BSc and MSc degrees in electrical engineering and computer science from MIT in US, Dr Hau has spent a few years performing hands-on software development at health related startups in Silicon Valley, and has held program director roles in health informatics at the US National Cancer Institute prior to moving to Australia in 2011.

Jane is the Director and Chief Operating Officer at the Australian Centre for AI in Medical Innovation (ACAMI), responsible for strategy, operations and partnerships across government, industry, and the research ecosystem.

Jane is a senior leader with over 25 years’ experience in pharmaceutical R&D and has previously held regional and global roles at Moderna, CSL Seqirus and GSK.

Jane’s work spans R&D, commercialisation, digital health and the integration of AI into medical research and medtech.

Jane is a qualified medical practitioner with business and governance qualifications and serves on advisory boards advancing biotechnology and workforce development.

‍

Dr Kushesh Gupta is a Senior Principal with ~15 years of experience in health care and life sciences, with more than 10 years of strategy consulting experience.

Kushesh has led multiple global projects for MedTech and Digital Health Technology clients, supporting them on business issues related to new product launch, market access, market opportunity assessment, GTM strategy and market entry strategy.

Kushesh is a medical doctor. After completing his MBBS (MD equivalent), he worked as a physician in a cardiac care. Kushesh went on to earn his MBA from IIM Ahmedabad

‍

Naveed’s experience spans medical technology, health services, consulting and academia with exposure to ANZ, EU and US markets. He is the regional lead for BIOTRONIK’s innovation initiatives across connected care, remote patient monitoring and workflow automation across chronic cardiac conditions (including cardiac implanted devices). At BIOTRONIK he supported the development and commercial launch of company’s first digital workflow solutions - HeartInsight® (for Heart Failure monitoring) and BMIV with SmartECG (for cardiac diagnostic monitoring). He also supported Advara HeartCare – Australia’s largest private cardiology network and a BIOTRONIK customer – with the implementation of a national remote monitoring model of care for all device patients during COVID.

Prior to BIOTRONIK, he spent a decade supporting translation of early-stage innovation, commercial research, and technology transfer activities across public and private sector organisations. Naveed started his career as a researcher investigating new molecular pathways in blood cancers at the Westmead Hospital / University of Sydney.

Olga is the Head of Funds Management at Innovation Victoria, where she manages the University Innovation Platform, a pre-seed co-investment program that partners with Victorian universities to back startups and spinouts emerging from their research. Her funds management work spans fund design, capital deployment governance and deal structuring. She also oversees the firm's investments in other VC funds and investments made through the Alice Anderson Fund.
‍

A Fellow Chartered Accountant with a PhD in Electrochemistry, Olga has co-founded a machine learning startup and worked in research commercialisation and capital markets across Australia and the UK. She is committed to backing founders whose companies will shape Australia's next generation of industries.

Paul is a specialist medical practitioner and the Chief Medical Officer for the Private Health Insurance arm of the Medibank Group, which includes the health delivery subsidiary Amplar Health.

Medibank is Australia’s largest and oldest private insurance provider and is rapidly evolving into one of Australia’s leading health companies as it delivers primary care, preventive health programs, acute care through its hospitals, as well as large virtual, community and aged care services.

Before Medibank, Paul was a Principal at the Nous Group for four years and led their Victorian health practice as well as the digital health practice for the firm.

Paul spent over 11 years in Chief Medical Officer roles at Western Health, Austin Health and Epworth Healthcare and is also a Fellow, examiner and previous Board director at the Royal Australasian College of Medical Administrators.

Paul is a Graduate of AICD, has sat on the MIPS medical indemnity insurance Board since January 2023, is a Fellow of the Australasian College of Health Service Management and a Research Fellow with the University of Melbourne’s Collaborative Practice Centre.

Dr Sarah Cavanagh is Chief Medical Officer – Digital Health at Wesfarmers Health, where she provides clinical leadership across the organisation's digital health businesses, including InstantScripts and SiSU Health. A Fellow of the Royal Australian College of General Practitioners (RACGP) with more than two decades of clinical experience, Sarah leads the development of clinical strategy, governance and innovation to ensure digital healthcare is safe, evidence-based and patient-centred.

Throughout her career, Sarah has championed the responsible integration of technology into healthcare, designing robust clinical pathways, strengthening governance frameworks and supporting multidisciplinary teams to deliver high-quality care at scale. She is a member of the Wesfarmers Health Clinical Governance Advisory Council and helped develop the Wesfarmers Telehealth Code of Practice.

Sarah is passionate about improving access to healthcare for all Australians and advancing the role of digital health in creating a more connected, sustainable and equitable health system.

Dr Simon Kos is an internationally recognised leader in digital health, working in senior executive roles for over twenty years. He is a registered medical practitioner who has practiced critical care medicine in Australia. He holds an MBBS from UNSW, an MBA from AGSM and is a Fellow of the Australian Institute of Digital Health (FAIDH).

Significant past roles include global chief medical officer of Microsoft based in Seattle, CEO of Next Practice, Physician Executive with Cerner, and the co-chair of the Global Commission to end the Diagnostic Odyssey for Children with a Rare Disease.

He is currently the global chief medical officer at Heidi Health, co-founder of Lumyra AI, an advisor to organisations and an investor in digital health start-ups.

Dr Tina Campbell is a health promotion and digital health specialist with over 20 years experience. She is the co-founder and CEO of Healthily, an Australian health technology company focused on advancing patient education and health literacy. Healthily collaborates with organisations across primary, tertiary and aged care to empower patients to take a more active role in their health journeys.

In 2015, Tina led the design and development of Healthily's flagship platform, GoShare Healthcare, now widely adopted by healthcare providers across Australia. In 2023, Healthily launched GoShare Voice, a voice AI solution that enables automated outbound and inbound calls, providing patients with education and information at scale while addressing digital literacy and language barriers.

Duane has spent over 25 years at the intersection of healthcare, strategy, and digital innovation, spanning startups, public health systems, and ASX-listed corporations.

As the founder of Potential(x), he raised capital and scaled the health data business into a global platform supporting more than 250 hospitals across Australia, New Zealand, and the UAE, ultimately culminating in a successful merger and ASX listing via Beamtree (ASX:BMT).

Currently the CEO of boutique venture and advisory firm The 4th, Duane actively shapes the future of the healthcare ecosystem. He serves as Board Chair for CoreSchedule (NZ SaaS); the Murrumbidgee PHN Innovation Committee; Director for Violet; Board Advisor for Hardy Group International and a strategic advisor to emerging healthcare companies including: Healthily and Consultmed.

Driven by curiosity and a commitment to enduring outcomes, Duane has mentored over 300 startups and remains deeply engaged in system-wide digital transformation.

Over his 40-year career Gavin has been a leader and champion of Medical Technology in Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is a strong advocate for Gender Equality and Indigenous Engagement. Gavin was a proud member of the Champions of Change Coalition STEM/Health group for 10 years and supports Red Dust Role Models.

Gavin is Non Executive Chair of ANDHealth (Australia’s National Digital Health Initiative) and Rhythm Biosciences (ASX: RHY). He is also a Non Executive Director of Omnigon Pty Ltd, Bowel Cancer Australia, SAN Foundation and United Way Australia. Most recently Gavin was CEO of Omnigon Pty Ltd, a private Australian company in the Ostomy Care market. And previously Gavin was Managing Director Australia/NZ and Vice President Asia Pacific for Johnson & Johnson Medical Devices (now Med Tech), Chair of the Medical Technology Association of Australia, Governor of American Chamber of Commerce, Co-Founder/Chair of Macquarie Park Business Coalition (in partnership with United Way) and Australian Co-Chair of the Health Technology Sector Group of the Australia/NZ Leadership Forum.

Gavin is a Graduate of the Australian Institute of Company Directors and has completed the AICD Boardroom Mastery program.

‍

Hari Srinivasan is the Head of AI Sales & Go-To-Market (GTM) for Google Cloud across Australia and New Zealand (ANZ). A seasoned technology commercial leader, Hari partners with the region’s largest enterprises to bridge the gap between cutting-edge artificial intelligence and tangible business outcomes.
‍

With a career built at the intersection of deep tech, strategic GTM execution, and enterprise sales, Hari leads high-performing teams that help organizations navigate complex AI transformations. He is passionate about moving AI past the proof-of- concept phase, enabling ANZ’s enterprise and startup ecosystems to deploy scalable, secure, and production-ready generative AI that drives genuine competitive advantage.
‍

Hari has a foundation in engineering and a Miami University MBA. Hari combines technical credibility with sharp commercial strategy to shape the future of enterprise AI in the region.

Since July 2018, Kate Quirke has been the Group Managing Director and Chief Executive Officer of the Alcidion Group, a company dedicated to providing smart technology to the health sector. Kate leads the business globally with current focus on Australia, New Zealand and the United Kingdom with a goal of developing mutually beneficial relationships with customers, partners and investors.

Kate has 25+ years of digital health sector experience and has been involved in large procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia. Her background includes leading management roles at large healthcare software firms where she has driven strategic product direction. She strongly believes that the astute application of information technology will support the transformation of healthcare delivery worldwide.

Kate is a Non-Executive Director of ANDHealth and previously served on the Board of the Stephanie Alexander Kitchen Garden Foundation for 16 years. During 2021, Kate was recognised as one of Telstra Health’s inaugural Brilliant Women in Digital Health and named Biotech Daily’s CEO of the Year. In 2020, Kate won the Executive Leader award in the inaugural B&T Women Leading Tech Awards. She received her Bachelor of Applied Science Health Information Management degree from Latrobe University.

Krystal Barter has spent over two decades building movements, changing laws, and proving that when patients are heard, healthcare improves for everyone.

As Founder and CEO of Humanise Health, a patient-led advocacy agency partnering with health businesses, advocates and government, Krystal is a recognised leader in genomics, preventive healthcare and health system reform.

Carrying the BRCA1 gene variant, she had a preventative double mastectomy at 25 and was one of the first Australians to publicly share her experience with hereditary cancer risk. She went on to found a women's health nonprofit, which she led for 14 years, raising millions for breast cancer research and became a leading voice on preventative health in Australia.

She was a driving force behind Australia's ban on genetic discrimination in life insurance and played a pivotal role in overturning the BRCA gene patent and establishing a global precedent, ensuring no corporation could own the rights to a human gene.

Krystal has co-authored peer-reviewed research, written a book, and produced a sold-out women's health event at the Sydney Opera House. Everything she has built rests on a single belief: that the most powerful force in healthcare is an informed, empowered patient.

Professor Peter Steel is an emergency physician, health-system executive and digital health leader focused on advancing clinical artificial intelligence and technology-enabled care to improve patient outcomes, workforce experience and health-system performance.

He serves as the University of Melbourne’s Associate Dean of Digital Health & Informatics and Director of the Centre for Digital Transformation of Health, and is the inaugural Chief Transformation Officer at the Royal Melbourne Hospital. In these roles, he leads work to advance data-driven and AI-enabled healthcare across patient care, medical research, education and health-service transformation.

Professor Steel earned his pre-clinical M.A. (Hons) at the University of Oxford and his medical degree from University College London–Royal Free Medical School. He completed emergency medicine residency at NewYork-Presbyterian/Columbia and Cornell in New York City, and practised as a board-certified attending emergency physician at NewYork-Presbyterian/Weill Cornell Medicine.

Prior to joining the University of Melbourne and the Royal Melbourne Hospital, he served as Vice Chair of Clinical Services in the Department of Emergency Medicine at Weill Cornell Medicine and as Associate Professor of Clinical Emergency Medicine. He also led a federally and industry-funded clinical AI research program focused on translating advanced digital intelligence into safer care, improved patient outcomes and stronger health-system performance.

Rachel is a partner at Giant Leap. Giant Leap invests in founders solving our most pressing global problems at scale across climate, health and people and has invested in over 30 companies to date.

Rachel is also on the Advisory Board for the Victorian Government’s Equity Investment Attraction Fund and formerly the Chair of the Startup Network, a non-profit, grassroots organisation supporting founders through their startup journey.

She has a background in management consulting and corporate finance, and previously co-founded a non-profit organisation to raise funds and awareness for MotorNeurone Disease

Samar Mcheileh is a transformative leader with over 15 years of experience in investment management and financial services, pioneering a new era of venture capital in Australia. Previously holding executive roles at wealth management firm JBWere, Samar was integral to the firm's transformation and sale from Goldman Sachs to NAB.

Samar is committed to a simple yet powerful thesis: the world's most innovative companies will be built by women. Her leadership is not just about capital; it's about creating a global community where visionary founders are backed by the resources, networks, and belief they need to succeed. Samar champions the belief that backing diverse founders is not a social mission—it's the smartest investment strategy. This commitment to equitable investment is further demonstrated by her work as co-creator of Equity Clear, a gender transparency initiative that was recognised on Fortune's "Change the World" list.